Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Oruka initiates dosing of first patient in Phase 1 trial of ORKA-001

Oruka Therapeutics (NASDAQ:ORKA) has announced the initiation of dosing of in its Phase 1 clinical trial of ORKA-001, a subcutaneously administered, half-life extended monoclonal antibody targeting IL-23p19. Inhibitors...

December 20, 2024

Executive Moves

Applied names John H. Johnson as EC; Shoshana Shendelman steps down as CEO

Applied Therapeutics (NASDAQ:APLT) has announced leadership changes, naming John H. Johnson as executive chairman (EC) and Les Funtleyder, formally CFO, as interim CEO. Shoshana Shendelman, MD, has stepped down from her...

December 20, 2024

Developments

FDA approval of Mesoblast’s RYONCIL bodes well for other cell therapy companies like BioRestorative Therapies and Cell Technologies

Mesoblast (ASX:MSB; NASDAQ:MESO) is rallying today after the company announced yesterday after market close that the FDA approved RYONCIL (remestemcel-L), an allogeneic (donor) bone marrow-derived mesenchymal stromal...

December 19, 2024

Executive Moves

Adicet appoints Julie Maltzman as CMO

Adicet Bio (NASDAQ:ACET) has appointed Julie Maltzman, MD, as chief medical officer (CMO), effective January 13, 2025. Adicet reports that Dr. Maltzman succeeds Dr. Francesco Galimi, who has completed his tenure with...

December 18, 2024

Developments

Silo initiates PK and tolerability study for non-opioid extended-release pain therapeutic

Silo Pharma (NASDAQ:SILO) has announced the initiation of a preclinical pharmacokinetic (PK) and tolerability study, in partnership with AmplifyBio, to assess Silo’s dissolvable, ketamine-based injectable implant, SP-26...

December 18, 2024

Developments

Larimar reports positive initial data from OLE study of nomlabofusp in FA

Larimar Therapeutics (NASDAQ:LRMR) has announced positive initial results from its ongoing open-label extension (OLE) study evaluating daily subcutaneous injections of 25 mg of nomlabofusp, either self-administered or...

December 16, 2024

Executive Moves

Jeb Ledell joins KalVista as COO

KalVista Pharmaceuticals (NASDAQ:KALV) has announced that Jeb Ledell has been appointed as chief operating officer (COO). Mr. Ledell brings more than 20 years of leadership and operational excellence in the...

December 16, 2024

Developments

MindMed announces first patient dosed in Phase 3 study of LSD in GAD

MindMed (NASDAQ:MNMD) has announced that the first patient has been dosed in its Phase 3 Voyage study of MM120, an orally disintegrating tablet (ODT) and pharmaceutically optimized form of LSD, in generalized anxiety...

December 16, 2024

Developments

Fractyl reveals promising preclinical data for pancreatic gene therapy program

Fractyl Health (NASDAQ:GUTS) has announced that it will present new data from its RJVA-001 Rejuva Smart GLP-1 pancreatic gene therapy program for the treatment of obesity and type 2 diabetes (T2D) at the 22nd World...

December 12, 2024

Executive Moves

Rockwell names Jesse Neri as CFO

Rockwell Medical (NASDAQ:RMTI) announced the promotion of Jesse Neri to chief financial officer (CFO). Mr. Neri, formally Rockwell’s senior vice president of finance, joined the company in 2023, bringing more than 25...

December 12, 2024

Markets

Clear Street initiates coverage of several healthcare stocks

Analysts Kaveri Pohlman, PhD and Bill Maughan, PhD from Clear Street, a cloud-native financial technology firm on a mission to modernize the brokerage ecosystem, have launched coverage of several healthcare names. “The...

December 11, 2024

Developments

Candel achieves primary endpoint in Phase 3 trial evaluating CAN-2409 in prostate cancer

Candel Therapeutics (NASDAQ:CADL) has announced results from its multicenter Phase 3 trial evaluating CAN-2409 viral immunotherapy in patients with localized prostate cancer. The study achieved its primary endpoint...

December 11, 2024

Oruka initiates dosing of first patient in Phase 1 trial of ORKA-001

Applied names John H. Johnson as EC; Shoshana Shendelman steps down as CEO

FDA approval of Mesoblast’s RYONCIL bodes well for other cell therapy companies like BioRestorative Therapies and Cell Technologies

Adicet appoints Julie Maltzman as CMO

Silo initiates PK and tolerability study for non-opioid extended-release pain therapeutic

Larimar reports positive initial data from OLE study of nomlabofusp in FA

Jeb Ledell joins KalVista as COO

MindMed announces first patient dosed in Phase 3 study of LSD in GAD

Fractyl reveals promising preclinical data for pancreatic gene therapy program

Rockwell names Jesse Neri as CFO

Clear Street initiates coverage of several healthcare stocks

Candel achieves primary endpoint in Phase 3 trial evaluating CAN-2409 in prostate cancer

General

More